Acadia Q3 net sales $130.7M (-1% YoY), net loss widens; trofinetide PDUFA Mar 2023

ACADIA PHARMACEUTICALS INC

2022-Q3 EPS reported -$1.08 revenue$130,714,000

Q3 net sales $130.7M (-1% YoY); net loss $27.2M ($0.17 loss/share) vs $14.5M loss a year ago.
FY 2022 NUPLAZID guidance narrowed to $510-520M from $510-540M; R&D and SG&A guides trimmed.
FDA accepted trofinetide NDA for Rett syndrome with priority review; PDUFA action date March 12, 2023.
President Serge Stankovic to retire at year-end; search ongoing. Adora Ndu appointed to Board of Directors.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ACADIA PHARMACEUTICALS INC reported third quarter ended September 30, 2022 results: revenue $130.7 million, net income $(0.17) per common share, EPS $(0.17) per common share. Guidance lowered.

Period: third quarter ended September 30, 2022
Revenue: $130.7 million
Net income: $(0.17) per common share
EPS: $(0.17) per common share
Guidance: lowered
Result: reported results

Exact text from the filing

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2022. NUPLAZID delivered net sales of $130.7 million in the third quarter of 2022

View on SEC.gov

Browse all earnings releases →

ACADIA PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0000950170-22-021222

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.